Nanobiotix SA

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

21 Jan 2025 01:30:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 Jan 2025 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

17 Dec 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Dec 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

09 Dec 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 Nov 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

12 Nov 2024 01:30:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Participate in Multiple Investor Conferences in November

31 Oct 2024 02:30:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Oct 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

18 Sep 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

04 Sep 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 Aug 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 Jul 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 Jun 2024 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jun 2024 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 May 2024 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 May 2024 01:00:00 By Nasdaq GlobeNewswire